Results 191 to 200 of about 969,879 (344)

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort   +8 more
wiley   +1 more source

Photon-Counting Coronary CT Angiography in Asymptomatic Patients With Extreme Coronary Artery Calcium Score. [PDF]

open access: yesJACC Adv
Shiyovich A   +6 more
europepmc   +1 more source

Human vs. artificial intelligence: Physicians outperform ChatGPT in real‐world pharmacotherapy counselling

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To assess the utility of the artificial intelligence (AI) chatbot ChatGPT (openly available version 3.5) in responding to real‐world pharmacotherapeutic queries from healthcare professionals. Methods Three independent and blinded evaluators with different levels of medical expertise and professional experience (beginner, advanced, and expert ...
Benjamin Krichevsky   +9 more
wiley   +1 more source

Does Competition Favor Delegation? [PDF]

open access: yes
This paper studies the consequences of product-market competition on firms' decisions to delegate more or fewer decision-making responsibilities to managers.
Christian Alejandro Ruzzier
core  

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy